2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations

EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the World Conference on Lung Cancer (WCLC) 2023 evaluated the efficacy and safety of aumolertinib as neoadjuvant and adjuvant therapy for patients with unresectable stage IIIA-IVA non-small cell lung cancer (NSCLC) with EGFR mutations. Neoadjuvant therapy with EGFR tyrosine kinase inhibitors (TKIs) has shown potential in improving outcomes for stage III lung cancer, which often has a low surgical resection rate.<br /><br />The study included 10 patients with unresectable, stage IIIA-IVA EGFR-mutant NSCLC who received aumolertinib. The median duration of neoadjuvant aumolertinib treatment was 10.4 weeks. All patients achieved an overall response rate (ORR) of 100%, and all underwent surgery, with minimally invasive surgery rates of 100% and achieving R0 resection.<br /><br />Of the patients who underwent pathological evaluation, 87.5% achieved major pathological response (MPR), and 25% achieved pathological complete response (pCR). Nodal downstaging was observed in 75% of patients. The median event-free survival (EFS) was not reached, and the 1-year and 2-year EFS rates were both 100%. Adverse events were mostly grades 1-2, with rash and diarrhea being the most common.<br /><br />The study found that neoadjuvant aumolertinib for 8-14 weeks resulted in higher response rates and MPR rates compared to historical data from other EGFR-TKIs. Notably, all patients, including those with stage IVA disease, achieved conversion from unresectable to resectable status. The study concludes that neoadjuvant and adjuvant aumolertinib showed satisfying efficacy with an excellent safety profile in unresectable NSCLC. Prolonging the neoadjuvant treatment duration may further enhance response rates and feasibility of surgery.<br /><br />In summary, this study suggests that neoadjuvant and adjuvant treatment with aumolertinib may be beneficial for patients with unresectable stage IIIA-IVA EGFR-mutant NSCLC, potentially enabling surgery and improving outcomes. Further research is needed to confirm these findings and optimize the duration of neoadjuvant treatment.

Asset Subtitle

ShenCun Fang

Meta Tag

Speaker ShenCun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023

aumolertinib

neoadjuvant therapy

unresectable stage IIIA-IVA

NSCLC

EGFR mutations

overall response rate

minimally invasive surgery

pathological complete response

safety profile